Daily Bulletin

Business Mentor


  • Written by PR Newswire Asia - Daily Bulletin Au RSS

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial in Australia.

MRX-5 is a new type of benzodiazepine antibiotic used to treat infections caused by NTMs (non-tuberculous mycobacteria). Non-tuberculosis mycobacteria refers to a large class of bacteria, excluding Mycobacteria tuberculosis, which causes chronic lung infections and results in lung damage and high mortality rates.  At least 250,000 people worldwide are actively being treated for NTM infections and incidence is increasing globally.

To date, more than 190 NTM species and 14 subspecies have been identified, with the most common pathogenic NTMs including the Mycobacterium abscess and the Mycobacterium avium complex. NTM infections require 12-24 months of antibiotic therapy taken multiple times per day.  Current treatments result in a high number of adverse reactions, inadequate clinical resolution, poor compliance and poor prognosis. Treatment of NTM patients, especially resistant patients, has significant unmet needs. New antibiotics which have greater efficacy, fewer adverse events and better patient compliance are urgently needed.

MicuRx is developing MRX-5 for treatment of refractory NTM infections.  Pre-clinical studies have shown that MRX-5 has good antibacterial activity for most common NTM bacteria and good safety in animal toxicology studies.

This Phase 1 study, the first human clinical trial of MRX-5, is conducted at the Nucleus Network Research Centre in Australia to assess the safety, tolerance, pharmacodynamic characteristics and food effects of oral MRX-5 in healthy subjects. The trial has previously been approved by the Australian Ethics Commission for Human Research (HREC) and has completed the clinical trial filing at the Therapeutic Goods Administration (TGA).  Completion is expected in 2024.

MicuRx is committed to advancing our pipeline products to serve the infectious disease and critical care markets where more therapeutic options are needed to address unmet medical needs.

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/4273363_CN73363_0

Business News

How to Get the Best Value When Buying Cardboard Boxes

Cardboard boxes have become an indispensable part of daily life, whether for moving houses, shipping products or simply for storage purposes. The key to making the most out of these versatile contai...

Daily Bulletin - avatar Daily Bulletin

BYD Expands in Australia: Introducing Chinese Dealerships and Pioneering Innovative Operations

Recently, BYD has been generating significant buzz with the launch of its two new stores in Melbourne and Sydney, revealing some exciting developments. Notably, BYD’s Chairman, Wang Chuanfu, graced ...

Daily Bulletin - avatar Daily Bulletin

Deciphering the Intricacies of Scrap Copper Prices in Melbourne: A Comprehensive Analysis

Introduction In the bustling metropolis of Melbourne, where innovation meets industry, the scrap copper market forms an integral part of the city's economic landscape. From the scrapyards scattered...

Daily Bulletin - avatar Daily Bulletin

Tomorrow Business Growth